Tag Archives: Keytruda

Germany’s Merck puts consumer drugs business up for sale; does this signal a last-ditch shot at M&A or just shoring up existing pipeline?

The News: Merck KGaA (Darmstadt DEU) put its consumer-health unit on the block Tuesday (September 5, 2017) in a move that will focus its healthcare activities on the riskier business… Read more »

Merck’s Keytruda aces another cancer trial as results dazzle researchers

The News: Hot on the heels of the final presentation at ASCO’s 4-day conference in Chicago, a small, new study is causing jaws to drop after it found that a… Read more »

ASCO, aka The Oncology Super Bowl for Biotechs, sends stocks in every direction

Steve’s Take: As another jam-packed annual meeting of the American Society of Clinical Oncology in Chicago wrapped up on Tuesday (June 6, 2017), with some 38,000 oncologists gathering together at… Read more »

Merck’s Keytruda gets chemo-combo approval for lung cancer; science, stars align for multi-billion medicine

The News: Merck & Co. announced Wednesday (May 10, 2017) that the FDA awarded accelerated approval to Keytruda (pembrolizumab), in combination with Eli Lilly & Co.’s chemotherapy regimen Alimta (pemetrexed)… Read more »

Pfizer’s mixed 1Q results spur M&A hopes; is Bristol-Myers a “done deal”?

The News: Pfizer Inc. said Tuesday (May 2, 2017) that first-quarter sales declined 2% year-over-year to $12.8 billion, missing analyst estimates of $13.1 billion, with the company highlighting one less… Read more »

OncoMed rocked by combo punch as cancer trial bombs and Bayer walks; CEO not about to raise white flag

The News: OncoMed Pharmaceuticals Inc. (Redwood City CA) began the week with a combination punch that some say spells a knockout in the near future. In back-to-back statements, OncoMed revealed… Read more »

Week’s opening stock roundup: gainers include Novocure, Steadymed; but Corvus, NewLink rocked

Here to start your trading week are the major movers from last week and where they stand this morning: Novocure (Nasdaq: NVCR) led advancing issues, soaring $3.25, or 40% over the… Read more »

German Merck, flying under Street’s radar, gets no respect; but not for long

Steve’s Take: Wall Street analysts are perhaps familiar with the history behind the two Pharma powerhouses, US-based Merck & Co., and Germany-based Merck KgaA. Until recently, however, I only had… Read more »

Icahn’s latest target, Bristol-Myers, may play hard-to-get; unless Pfizer comes a courting

The News: Activist investor Carl Icahn just announced his latest target: Bristol-Myers Squibb Co., reports the Wall Street Journal. Bristol-Myers has been the focus of several activist investors in recent… Read more »

Bristol Myers cuts guidance on cancer drug issues; shareholders scanning skies for vultures with deep pockets

The News: Bristol-Myers Squibb Co. (New York City) cut its earnings guidance for the year as the drugmaker contends with dimmed prospects for its top cancer drug after major setbacks… Read more »